Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Envoy Medical Inc.(COCH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for COCH
11/13/2026: COCH (1-star) is currently NOT-A-BUY. Pass it for now.
Envoy Medical Inc. is an emerging medical technology company specializing in fully implanted hearing systems, such as its signature Esteem device. The company offers a unique, invisible alternative to traditional hearing aids, which is its primary competitive strength. Its growth story is centered on clinical trial success and gaining wider market adoption through physician education. However, investors face significant risks, including the high cost of implementation, competition from established global giants, and complex regulatory and reimbursement hurdles. The stock is best suited for growth-oriented investors with a high risk tolerance who are looking to monitor the company's progress toward sustained commercialization and clinical validation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers potential high growth tied to product innovation but faces significant execution and regulatory risks. |
| Momentum investor | Mixed fit | Momentum depends heavily on positive catalysts such as major regulatory wins or clinical milestones. |
| Value investor | Weak fit | The company is in an early growth/development stage and lacks the stable cash flows and valuation metrics favored by value investors. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses all capital on growth and development. |
| Low-risk investor | Weak fit | The inherent risks of the biotech and medical device industry make this an unsuitable choice for risk-averse portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to sharp price swings based on clinical trial results and regulatory updates. |
| Valuation risk | High | Valuations are heavily speculative and based on long-term adoption expectations rather than current earnings. |
| Competition risk (hearing device giants) | Medium / high | The company faces intense competition from established global entities with massive R&D budgets. |
| Business quality | Medium | The core technology is innovative, but commercial scale and market penetration are still in the early stages. |
| Dividend income | Low / none | There is no income component to the investment thesis. |
| Execution risk | High | Success depends on complex regulatory pathways and surgical adoption of their technology. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 52.74M USD | Price to earnings Ratio - | 1Y Target Price 19.67 |
Price to earnings Ratio - | 1Y Target Price 19.67 | ||
Volume (30-day avg) 25.4K shares | Beta 2.02 | 52 Weeks Range 3.63 - 9.54 | Updated Date 11/13/2026 |
52 Weeks Range 3.63 - 9.54 | Updated Date 11/13/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.57 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Devices
- BUY participation
- 62.5%
- Active BUY / eligible
- 5 / 8
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -55.33% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Hearing Implant Devices | Sales of the Esteem fully implanted hearing device and associated clinical services. | Revenue is generated from selling advanced, implantable hearing technology to healthcare providers and surgical centers. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 40.00M | Price to Sales(TTM) 254.78 |
Enterprise Value 40.00M | Price to Sales(TTM) 254.78 | ||
Enterprise Value to Revenue 173.14 | Enterprise Value to EBITDA -1.35 | Shares Outstanding 7.74M | Shares Floating 4.32M |
Shares Outstanding 7.74M | Shares Floating 4.32M | ||
Percent Insiders 40.23 | Percent Institutions 23.29 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.